The DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
Open accessAbstract
Anaplastic lymphoma kinase (ALK) activation has been associated with many types of human cancer. Significant efforts have been devoted to the development of ALK inhibitors to antagonize the kinase activity of ALK. Four ALK inhibitors have been approved by the FDA to date for treating patients with ALK-positive non-small cell lung cancers (NSCLC). However, drug resistance has been observed in the majority of patients treated with these inhibitors. New therapeutic strategies (e.g., compounds with novel mechanisms of action) are needed to overcome the drug resistance issue. The emerging PROTAC (Proteolysis Targeting Chimera) technology has been successfully applied to selective degradation of multiple protein targets, but not ALK. Since ALK protein levels are not important for viability in mammals, ALK PROTACs could lead to novel therapeutics with minimal toxicity. Here we report the design, synthesis and biological evaluation of novel PROTACs (degraders) of ALK. MS4077 (5) and MS4078 (6) potently decreased cellular levels of oncogenic active ALK fusion proteins in a concentration- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells. The ALK protein degradation induced by compounds 5 and 6 was cereblon and proteasome dependent. In addition, compounds 5 and 6 potently inhibited proliferation of SU-DHL-1 cells. Furthermore, compound 6 displayed good plasma exposure in a mouse pharmacokinetic study, thus is suitable for in vivo efficacy studies. We also developed MS4748 (7) and MS4740 (8), very close analogs of 5 and 6 respectively, which are incapable to degrade the ALK fusion proteins, as negative controls. Compounds 5-8 are valuable chemical tools for investigating effects of ALK pharmacological degradation. Our study paved the way for developing the next generation of ALK PROTACs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, PROTACs were shown to be substrates for MDR1 (10, 13), suggesting that drug efflux represents a potential limitation for degrader therapies.”
From The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells (2022) · cites this paper as [13]
In the citing paper
“A number of PROTACs have been developed to target various POIs that are involved in the tumorigenesis and progression of hematologic malignancies, such as anaplastic lymphoma kinase (ALK) [5], Bcl-xL [4], BCR-ABL [6], Bruton’s tyrosine kinase (BTK) [7], BRD4 [8], CDK-6 [9], FMS-like tyrosine kinase-3 (FLT-3) [10], HDAC6 [11], and signal transducer and activator of transcription 3 (STAT3) [3].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [5]
In the citing paper
“Recently, the anaplastic lymphoma kinase (ALK) was degraded by two PROTACs based on a pomalidomide warhead targeting CRBN linked with either LDK378 (ceritinib) [79, 80] or TAE684 [79] targeting ALK.”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [80]
In the citing paper
“Both PROTACs were able to reduce downstream signalling and proliferation of ALK-driven cell lines by degrading ALK [79, 80].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,428
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M. B., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,923
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Proteasome inhibitors: valuable new tools for cell biologists.
Lee, D. H., & Goldberg, A. L. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01346-4 · Cited by 1,474
Cited by
Sorted by citations
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,813
PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 830
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 850
Advancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K., Kanıskan, H. Ü., Xiong, Y., & Jin, J. J. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00365-x · Cited by 697
Self-citationPROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y.-G., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 663
Targeted protein degradation: elements of PROTAC design
Paiva, S.-L., & Crews, C. M. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.02.022 · Cited by 598
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Li, X., Pu, W., Zheng, Q., Ai, M., Chen, S., & Peng, Y. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01434-3 · Cited by 389
Zhang, L., Riley-Gillis, B., Vijay, P., & Shen, Y. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1129 · Cited by 365
An, S., & Fu, L. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.005 · Cited by 363
Zoppi, V., Hughes, S. J., Maniaci, C., Testa, A., Gmaschitz, T., Wieshofer, C., Koegl, M., Riching, K. M., Daniels, D. L., Spallarossa, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01413 · Cited by 336
Degradation of proteins by PROTACs and other strategies
Wang, Y., Jiang, X., Feng, F., Liu, W., & Sun, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.001 · Cited by 335
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action
Riching, K. M., Mahan, S. D., Corona, C. R., McDougall, M. G., Vasta, J. D., Robers, M. B., Urh, M., & Daniels, D. L. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00692 · Cited by 310
Cancer Selective Target Degradation by Folate-Caged PROTACs
Liu, J., Chen, H., Liu, Y., Shen, Y., Meng, F., Kanıskan, H. Ü., Jin, J. J., & Wei, W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00451 · Cited by 314
Self-citationThe PROTAC technology in drug development
Zou, Y., Ma, D., & Wang, Y. (2019) · Cell Biochemistry and Function · doi:10.1002/cbf.3369 · Cited by 312
Light-induced control of protein destruction by opto-PROTAC
Liu, J., Chen, H., Ma, L., He, Z., Wang, D., Liu, Y., Lin, Q., Zhang, T., Gray, N. S., Kanıskan, H. Ü., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay5154 · Cited by 310
Self-citationTargeted protein degradation: A promise for undruggable proteins
Samarasinghe, K. T. G., & Crews, C. M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.011 · Cited by 297
Hu, J., Hu, B., Wang, M., Xu, F., Miao, B., Yang, C., Wang, M., Liu, Z., Hayes, D. F., Chinnaswamy, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01572 · Cited by 286
Zeng, S., Huang, W., Zheng, X., Cheng, L., Zhang, Z., Wang, J., & Shen, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112981 · Cited by 264
Cheng, M., Yu, X., Lu, K. J., Xie, L., Wang, L., Meng, F., Han, X., Chen, X., Liu, J., Xiong, Y., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01566 · Cited by 197
Self-citationALK-positive lung cancer: a moving target
Schneider, J. L., Lin, J. J., & Shaw, A. T. (2023) · Nature Cancer · doi:10.1038/s43018-023-00515-0 · Cited by 198
Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule
Zhao, Q., Lan, T., Su, S., & Rao, Y. (2018) · Chemical Communications · doi:10.1039/c8cc07813k · Cited by 187
Harnessing the Power of Proteolysis for Targeted Protein Inactivation
Verma, R., Mohl, D., & Deshaies, R. J. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.01.010 · Cited by 185
PROTACs– a game-changing technology
Konstantinidou, M., Li, J., Zhang, B., Wang, Z., Shaabani, S., ter Brake, F., Essa, K., & Dömling, A. S. S. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1659242 · Cited by 171
Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta
Bai, N., Miller, S. A., Andrianov, G. V., Yates, M., Kirubakaran, P., & Karanicolas, J. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01451 · Cited by 157
Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs
Girardini, M., Maniaci, C., Hughes, S. J., Testa, A., & Ciulli, A. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.048 · Cited by 163
The role of reversible and irreversible covalent chemistry in targeted protein degradation
Kiely‐Collins, H., Winter, G. E., & Bernardes, G. J. L. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.005 · Cited by 160
Developments of CRBN-based PROTACs as potential therapeutic agents
Wang, C., Zhang, Y., Wu, Y., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113749 · Cited by 158
The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination
Jin, J., Wu, Y., Chen, J., Shen, Y., Zhang, L., Zhang, H., Chen, L., Yuan, H., Chen, H., Zhang, W., et al. (2020) · Theranostics · doi:10.7150/thno.46985 · Cited by 148
Self-citationProteolysis-targeting chimeras with reduced off-targets
Nguyen, T. M., Sreekanth, V., Deb, A., Kokkonda, P., Tiwari, P. K., Donovan, K. A., Shoba, V. M., Chaudhary, S. K., Mercer, J. A. M., Lai, S., et al. (2023) · Nature Chemistry · doi:10.1038/s41557-023-01379-8 · Cited by 141
The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
Kurimchak, A. M., Herrera-Montávez, C., Montserrat-Sangrà, S., Araiza-Olivera, D., Hu, J., Neumann-Domer, R., Kuruvilla, M., Bellacosa, A., Testa, J. R., Jin, J., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abn2707 · Cited by 136
Self-citationDrug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)
Kong, X., Pan, P., Sun, H., Xia, H., Wang, X., Li, Y., & Hou, T. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00446 · Cited by 135
Kang, C. H., Lee, D.-H., Lee, C. O., Ha, J. D., Park, C. H., & Hwang, J. Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.09.169 · Cited by 126
Chen, H., Liu, J., Kanıskan, H. Ü., Wei, W., & Jin, J. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00901 · Cited by 129
Self-citationProteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126
Bashraheel, S. S., Dömling, A. S. S., & Goda, S. K. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110009 · Cited by 128
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update
Wu, T., Qin, Z., Tian, Y., Wang, J., Xu, C., Li, Z., & Bian, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00744 · Cited by 119
Bivalent Ligands for Protein Degradation in Drug Discovery
Scheepstra, M., Hekking, K. F. W., Hijfte, L. V., & Folmer, R. H. A. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.01.006 · Cited by 125
Strategies for designing proteolysis targeting chimaeras (PROTACs)
He, S., Dong, G., Cheng, J., Wu, Y., & Sheng, C. (2022) · Medicinal Research Reviews · doi:10.1002/med.21877 · Cited by 120
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Kelm, J. M., Pandey, D. S., Malin, E., Kansou, H. W., Arora, S., Kumar, R., & Gavande, N. S. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01707-5 · Cited by 122
Plasticity in designing PROTACs for selective and potent degradation of HDAC6
Yang, H., Lv, W., He, M., Deng, H., Li, H., Wu, W., & Rao, Y. (2019) · Chemical Communications · doi:10.1039/c9cc08509b · Cited by 108
Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders
Shen, Y., Gao, G., Yu, X., Kim, H., Wang, L., Xie, L., Schwarz, M. C., Chen, X., Guccione, E., Liu, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01111 · Cited by 107
Self-citationDiscovery of potent small molecule PROTACs targeting mutant EGFR
Zhao, H., Yang, X., Lei, H., Xi, X.-X., Lu, S., Zhang, J., Xin, M., & Zhang, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112781 · Cited by 107
Self-citationBensimon, A., Pizzagalli, M. D., Kartnig, F., Dvorak, V., Essletzbichler, P., Winter, G. E., & Superti-Furga, G. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.04.003 · Cited by 102
Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality
Kostić, M., & Jones, L. H. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.02.006 · Cited by 100
Novel immunomodulatory drugs and neo-substrates
Gao, S., Wang, S., & Song, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-0182-y · Cited by 95
Advances in targeted degradation of endogenous proteins
Röth, S., Fulcher, L. J., & Sapkota, G. P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03112-6 · Cited by 92
Cao, C.-G., Yang, J., Chen, Y. X., Zhou, P., Wang, Y., Du, W., Zhao, L., & Chen, Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00821 · Cited by 88
PROTAC therapy as a new targeted therapy for lung cancer
Li, J. W., Zheng, G., Kaye, F. J., & Wu, L. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.011 · Cited by 87
Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
Gao, J., Yang, L., Lei, S., Zhou, F., Nie, H., Peng, B., Xu, T., Chen, X., Yang, X., Sheng, C., et al. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.04.028 · Cited by 89
Self-citationPiperlongumine conjugates induce targeted protein degradation
Pei, J., Xiao, Y., Liu, X., Hu, W., Sobh, A., Yuan, Y., Zhou, S., Hua, N., Mackintosh, S. G., Zhang, X., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.01.004 · Cited by 87
Sun, N., Ren, C., Kong, Y., Zhong, H., Chen, J., Li, Y., Zhang, J., Zhou, Y., Qiu, X., Lin, H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112190 · Cited by 85
Self-citationWang, Y., Han, L., Liu, F., Yang, F., Jiang, X., Sun, H., Feng, F., Xue, J., & Liu, W. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.110795 · Cited by 82
Chemoselective Synthesis of Lenalidomide-Based PROTAC Library Using Alkylation Reaction
Qiu, X., Sun, N., Kong, Y., Li, Y., Yang, X., & Jiang, B. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b01326 · Cited by 80
Self-citationDevelopment of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)
Xie, S., Sun, Y., Liu, Y., Li, X., Li, X., Zhong, W., Zhan, F., Zhu, J., Yao, H., Yang, D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00270 · Cited by 81
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
Wu, X., Yang, X., Xiong, Y., Li, R., Ito, T., Ahmed, T. A., Karoulia, Z., Adamopoulos, C., Wang, H., Wang, L., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00174-z · Cited by 75
Self-citationDesigning Chimeric Molecules for Drug Discovery by Leveraging Chemical Biology
Borsari, C., Trader, D. J., Tait, A., & Costi, M. P. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01456 · Cited by 76
Chen, S., Cui, J., Chen, H., Yu, B., & Long, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115911 · Cited by 70
Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality
Chamberlain, P. P., D’Agostino, L. A., Ellis, J. M., Hansen, J. D., Matyskiela, M. E., McDonald, J. J., Riggs, J. R., & Hamann, L. G. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00425 · Cited by 69
Yang, L., Tu, W., Huang, L., Miao, B., Kaneshige, A., Jiang, W., Leng, L., Wang, M., Wen, B., Sun, D., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00953 · Cited by 67
Targeting ALK Rearrangements in NSCLC: Current State of the Art
Peng, L., Zhu, L., Sun, Y., Stebbing, J., Selvaggi, G., Zhang, Y., & Yu, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.863461 · Cited by 71
Monitoring and deciphering protein degradation pathways inside cells
Daniels, D. L., Riching, K. M., & Urh, M. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.12.001 · Cited by 65
Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader
Wei, J., Hu, J., Wang, L., Xie, L., Jin, M. S., Chen, X., Liu, J., & Jin, J. J. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01528 · Cited by 67
Self-citationSmall molecule PROTACs: an emerging technology for targeted therapy in drug discovery
Pei, H., Peng, Y., Zhao, Q., & Chen, Y. (2019) · RSC Advances · doi:10.1039/c9ra03423d · Cited by 70
Discovery of Selective Small Molecule Degraders of BRAF-V600E
Han, X., Chen, L., Wei, Y., Yu, W., Chen, Y., Zhang, C., Jiao, B., Shi, T., Sun, L., Zhang, C., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02083 · Cited by 64
Self-citationProteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
Li, R., Liu, M., Yang, Z., Li, J., Gao, Y., & Tan, R. (2022) · Molecules · doi:10.3390/molecules27248828 · Cited by 69
Shagufta, Ahmad, I., Mathew, S., & Rahman, S. (2020) · RSC Medicinal Chemistry · doi:10.1039/c9md00570f · Cited by 64
Li, M., Yang, Y., Zhao, Q., Wu, Y., Song, L., Yang, H., He, M., Gao, H., Song, B., Luo, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00339 · Cited by 65
Update on the Development of MNK Inhibitors as Therapeutic Agents
Xu, W., Kannan, S., Verma, C. S., & Nacro, K. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00368 · Cited by 63
Journey of PROTAC: From Bench to Clinical Trial and Beyond
Berkley, K., Zalejski, J., Sharma, N., & Sharma, A. K. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00577 · Cited by 62
Novel targeted therapies of T cell lymphomas
Iżykowska, K., Rassek, K., Korsak, D., & Przybylski, G. K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01006-w · Cited by 60
Targeted degradation of extracellular secreted and membrane proteins
Chen, X., Zhou, Y., Zhao, Y., & Tang, W. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.08.013 · Cited by 59
Discovery of a PROTAC targeting ALK with in vivo activity
Yan, G., Zhong, X.-X., Lin, Y., Pu, C., Shan, H., Lan, S., Zhou, M., Hou, X., Yang, J., & Li, R. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113150 · Cited by 59
Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Salerno, A., Seghetti, F., Caciolla, J., Uliassi, E., Testi, E., Guardigni, M., Roberti, M., Milelli, A., & Bolognesi, M. L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00302 · Cited by 58
Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation
Xi, M., Chen, Y., Yang, H., Xu, H., Du, K., Wu, C., Xu, Y., Deng, L., Luo, X., Yu, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.036 · Cited by 57
Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders
Chen, L., Chen, Y., Zhang, C., Jiao, B., Liang, S., Qiong, T., Chai, H., Yu, W., Qian, Y., Yang, H., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01342 · Cited by 55
Self-citationA critical evaluation of the approaches to targeted protein degradation for drug discovery
Chopra, R., Sadok, A., & Collins, I. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.002 · Cited by 53
Desai, A. P., & Lovly, C. M. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-708 · Cited by 55
Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions
Gao, Y., Jiang, B., Kim, H., Berberich, M. J., Che, J., Donovan, K. A., Hatcher, J. M., Huerta, F., Kwiatkowski, N. P., Liu, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01864 · Cited by 51
Self-citationProteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation
Ruffilli, C., Röth, S., Rodrigo, M., Boyd, H., Zelcer, N., & Moreau, K. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00142 · Cited by 51
Ren, C., Sun, N., Kong, Y., Qu, X., Liu, H., Zhong, H., Song, X., Yang, X., & Jiang, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113335 · Cited by 50
Self-citationResearch progress of MEK1/2 inhibitors and degraders in the treatment of cancer
Wang, C., Wang, H., Zheng, C., Liu, Z., Gao, X., Xu, F., Niu, Y., Zhang, L., & Xu, P. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113386 · Cited by 49
Maksoud, S. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02339-4 · Cited by 48
Song, X., Zhong, H., Qu, X., Yang, L., & Jiang, B. (2021) · MedComm · doi:10.1002/mco2.42 · Cited by 48
Self-citationVenkatesan, J., Murugan, D., Lakshminarayanan, K., Smith, A. R., Thirumalaiswamy, H. V., Kandhasamy, H., Zender, B., Zheng, G., & Rangasamy, L. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108725 · Cited by 48
Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment
Zhang, J., Gao, Y., Zhang, Z., Zhao, J., Jia, W., Xia, C., Wang, F., & Liu, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01352 · Cited by 49
Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)
Zhang, Z., Chang, X., Zhang, C., Zeng, S., Liang, M., Ma, Z., Wang, Z., Huang, W., & Shen, Z. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1804382 · Cited by 46
Self-citationChemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets.
Moon, S., & Lee, B. (2018) · Europe PMC (PubMed Central) · doi:10.14348/molcells.2018.0372 · Cited by 47
Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities
Song, R., Qiao, W., He, J., Huang, J., Luo, Y., & Yang, T. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01640 · Cited by 45
Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation
Yan, J., Li, T., Miao, Z., Wang, P., Sheng, C., & Zhuang, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00728 · Cited by 46
Hu, J., Wei, J., Yim, H., Wang, L., Xie, L., Jin, M. S., Kabir, M., Qin, L., Chen, X., Liu, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01609 · Cited by 43
Self-citationYu, X., Xu, J., Shen, Y., Cahuzac, K. M., Park, K., Dale, B., Liu, J., Parsons, R. E., & Jin, J. J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02165 · Cited by 43
Self-citationDegraders in epigenetic therapy: PROTACs and beyond
Dai, X., Ji, S., Fu, M., Liu, G.-Z., Liu, H., Wang, S., Shen, L., Wang, N., Herdewijn, P. A., Zheng, Y., et al. (2024) · Theranostics · doi:10.7150/thno.92526 · Cited by 45
Induced proximity-based therapeutic modalities
King, E. A., Meyers, M., & Nomura, D. K. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01316-z · Cited by 61
Aboelez, M. O., Belal, A., Xiang, G., & Ma, X. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2062338 · Cited by 42
Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?
Cieślak, M., & Słowianek, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030812 · Cited by 42
ALK in cancer: from function to therapeutic targeting
Voena, C., Ambrogio, C., Iannelli, F., & Chiarle, R. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00797-9 · Cited by 49
Ren, C., Sun, N., Liu, H., Kong, Y., Sun, R., Qiu, X., Chen, J., Li, Y., Zhang, J., Zhou, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00373 · Cited by 41
Self-citationManeiro, M., Vita, E. D., Conole, D., Kounde, C. S., Zhang, Q., & Tate, E. W. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.002 · Cited by 38
Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
Liu, J., Peng, Y., & Wei, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.678077 · Cited by 38
Self-citation
Metadata
- Authors
- Zhang, C., Han, X.-R., Yang, X., Jiang, B., Liu, J., Xiong, Y., & Jin, J.
- Affiliations
- Tisch Cancer Institute (US)
- ShanghaiTech University (CN)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Liu, Jing
- Xiong, Yue
- Jin, Jian
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 151
- Pages
- 304-314
- ISSN
- 0223-5234 (ISSN-L)
- PMC
- PMC5924614
- OpenAlex
- W2794623623
- Cited by
- 226
- References
- 57
- Citations by year
- 2026: 17 · 2025: 23 · 2024: 24 · 2023: 26 · 2022: 31 · 2021: 31 · 2020: 38 · 2019: 26 · 2018: 9
- FWCI
- 9.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- European Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U. S. National Institutes of Health (R01GM067113)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, anaplastic lymphoma kinase, cereblon ligands, proteasomal degradation, ALK fusion proteins, drug resistance, non-small cell lung cancer, ALK-positive lymphoma, pharmacokinetics, kinase inhibitors
- MeSH terms
- Anaplastic Lymphoma Kinase, Animals, Antineoplastic Agents, Humans, Lung Neoplasms, Lymphoma, Male, Drug Design, Signal Transduction, Receptor Protein-Tyrosine Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mice, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
